PROTAC for Bruton’s tyrosine kinase degradation alleviates inflammation in autoimmune diseases

Can Zhu(Wuhan University of Science and Technology), Wanli Liu(Center for Life Sciences), Jingwen Wang(Shanxi Medical University), Bing Yang(University of Missouri), Ning Ding(University Hospital Bonn), Zhenjun Li(Northeast Agricultural University), Yu Rao(Soochow University), Na Young Kang(Center for Life Sciences), Yu‐Xiao Zhang(Chinese General Hospital College of Nursing and Liberal Arts), Zimo Yang(University of Electronic Science and Technology of China), Yonghui Sun(Tsinghua University), Guangchen Li(Shandong Jiaotong University)
Cell Discovery
August 6, 2024
10.1038/s41421-024-00711-x
Cited by 22

Related Papers

PROTACs: great opportunities for academia and industry
|Signal Transduction and Targeted Therapy|2019|627
Crystal structure of a bacterial homologue of glucose transporters GLUT1–4
|Nature|2012|488
PROTAC Technology: Opportunities and Challenges
|ACS Medicinal Chemistry Letters|2020|353
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
|The Lancet Neurology|2019|286
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
|Cell Research|2018|280